NCT06034275View on ClinicalTrials.gov

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

PHASE1RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

September 13, 2023

Primary Completion Date

May 30, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid LeukemiaB-cell Acute Lymphoblastic LeukemiaHigh-risk Myelodysplastic Syndrome
Interventions
DRUG

VIP943 (QW)

VIP943 will be administered by IV Infusion weekly

DRUG

VIP943 (BIW)

VIP943 will be administered by IV Infusion bi-weekly

Trial Locations (5)

35233

RECRUITING

University of Alabama at Birmingham, Birmingham

37203

RECRUITING

TriStar Bone Marrow Transplant, Nashville

45219

RECRUITING

University of Cincinnati, Cincinnati

77030

RECRUITING

MD Anderson Cancer Center, Houston

98109

RECRUITING

Fred Hutchinson Cancer Center, Seattle

All Listed Sponsors
lead

Vincerx Pharma, Inc.

INDUSTRY